Acquired resistance to anti-EGFR antibodies in metastatic colorectal cancer

Abstract

Li Minmin, Bi Xiang, Wang Zhehai. Acquired resistance to anti-EGFR antibodies in metastatic colorectal cancer[J]. Journal of International Oncology, 2014, 41(5): 357-360.

［1］ Bardelli A, Jnne PA. The road to resistence: EGFR mutation and cetuximab［J］. Nat Med, 2012, 18(2):199-200. ［2］ Montagut C, Dalmases A, Bellosillo B, et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistence in colorectal cancer［J］. Nat Med, 2012, 18(2):221-223. ［3］ Wheeler DL, Huang S, Kruser TJ, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members［J］. Oncogene, 2008, 27(28):3944-3956. ［4］ Lu Y, Li X, liang K, et al. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistence escaping treatment by the antiEGFR monoclonal antibody cetuximab［J］. Cancer Res, 2007, 67(17):8240-8247. ［5］ Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to antiEGFR therapy in colorectal cancer［J］. Nature, 2012, 486(7404):532-536. ［6］ Diaz LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquiredresistance to targeted EGFR blockade in colorectal cancers［J］. Nature, 2012, 486(7404):537-540. ［7］ Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab［J］. Cancer Biol Ther, 2011, 11(9):777792. ［8］ Ciardiello F, Bianco R, Caputo R. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor,in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy［J］. Clin Cancer Res, 2004, 10(2):784-793. ［9］ Vallbhmer D, Zhang W, Gordon M, et al. Molecular determinants of cetuximab efficacy［J］. J Clin Oncol, 2005, 23(15):3536-3544. ［10］ Li C, Iida M, Dunn EF, et al. Nuclear EGFR contributes to acquired resistence to cetuximab［J］. Oncogene, 2009, 28(43):3801-3813. ［11］ OliverasFerraros C, Massaguer VallLlovera A, Carrion Salip D, et al. Evolution of the predictive markers amphiregulin and epiregulin mRNA during long term cetuximab treatment of KRAS wild type tumor cells［J］. Invest New Drugs, 2012, 30(2):846-852. ［12］ Kim SM, Kim JS, Kim JH, et al. Acquired resistance to cetuximab is mediated by increased PTEN instability and lead crossresistance to gefitinib in HCC827 NSCLC cells［J］. Cancer Lett, 2010, 296(2):150159. ［13］ Wheeler DL, Lida M, Kruser TJ, et al. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab［J］. Cancer Biol Ther, 2009, 8(8):696-703. ［14］ Santini D, Vincenzi B, Addeo R, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?［J］. Ann Oncol, 2012, 23(9):2313-2318. ［15］ Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase Ⅲ trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer［J］. J Clin Oncol, 2008, 26(14):2311-2319. ［16］ Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer［J］. N Engl J Med, 2004, 351(4):337-334. ［17］ Matar P, Rojo F, Cassia R. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMGC225): superiority over singleagent receptor targeting［J］. Clin Cancer Res, 2004, 10(19):6487-6501. ［18］ Dunn EF, Iida M, Myers RA, et al. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab［J］. Oncogene, 2011, 30(5):561-574. ［19］ Garrett JT, Arteaga CL. Resistance to HER2directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications［J］. Cancer Biol Ther, 2011,11(9):793-800. ［20］ Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international,multicentre, randomised, placebocontrolled, phase 3 trial［J］. Lancet, 2013, 381(9863):303-312.

[1]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[4]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[5]	Gong Yan, Chen Honglei.Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer[J]. Journal of International Oncology, 2024, 51(3): 186-190.
[6]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[7]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong.Expression and clinical significance of ASB6 in colorectal cancer tissues[J]. Journal of International Oncology, 2023, 50(8): 470-474.
[8]	An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui.Research progress of Nrf2 in ovarian cancer[J]. Journal of International Oncology, 2023, 50(8): 493-497.
[9]	Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356.
[10]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing.Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer[J]. Journal of International Oncology, 2023, 50(5): 268-273.
[11]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun.Construction of postoperative prognosis model for patients with colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 157-163.
[12]	Xu Liangfu, Li Yuanfei.Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 186-190.
[13]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng.Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer[J]. Journal of International Oncology, 2023, 50(12): 717-722.
[14]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu.Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer[J]. Journal of International Oncology, 2023, 50(11): 683-687.
[15]	Liu Xiaojie, Huang Junxing.Research progress of NADPH oxidase 2 in malignant tumors[J]. Journal of International Oncology, 2023, 50(10): 618-621.

Acquired resistance to anti-EGFR antibodies in metastatic colorectal cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments